KRAKOW, Poland, Sept. 3, 2019 /PRNewswire/ -- Selvita (WSE: SLV) today announced that Pawel Przewiezlikowski, Chief Executive Officer, will present at the following conferences in New York: Event: H.C. Wainwright 21st Annual Global Investment Conference, Sept. 8-10, 2019

TAIPEI, Taiwan, Sept. 3, 2019 /PRNewswire/ -- OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-999 to conduct a Phase 1/2 study of its antibody drug conjugate (ADC) cancer therapy targeting Globo H, a

PARAMUS, N.J., Sept. 3, 2019 /PRNewswire/ -- Sony plans to release a new, more user-friendly workflow version of its modality-neutral NUCLeUS™ medical imaging plat

LINKÖPING, Sweden, Sept. 3, 2019 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) reported growth in all operating areas du

CHICAGO, Sept. 3, 2019 /PRNewswire/ -- At the American Society for Radiation Oncology (ASTRO) 2019 Annual Meeting, September 15-18 in Chicago, Elekta (EKTA-B.ST) will highlight its growing portfolio of innovative solutions that are making Precision Radiation Medicine the new standard in value-based healthcare

BASEL, Switzerland, Sept. 3, 2019 /PRNewswire/ -- Strekin AG (www.strekin.com), a clinical stage biopharmaceutical company, announced today that it has successfully closed a Series A financing round totaling CHF 2.82 Million from private investors. These funds will enable Strekin to conclud

STOCKHLOM, Sept. 3, 2019 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it has obtained written feedback from the US Food and Drug Administration (FDA) that will have a significant impact on the ongoing pivotal Phase 3 study, NefIgArd, with Calliditas' leading drug candidate Nefecon for the chronic autoimmune kidney disease IgA Nephropathy (IgAN). Cal

GDAŃSK, Poland, Sept. 3, 2019 /PRNewswire/ -- Polpharma Biologics S.A. ("Polpharma Biologics") today announces that it has entered a global commercialization agreement with Sandoz AG for a natalizumab biosimilar. The medicine is currently in Phase III clinical development for the treatment of relapsing-remitting multiple sclerosis (RRMS). Under this agreement, Polph

SHANGHAI, Sept. 3, 2019 The first-ever Asia Pacific Psychiatric Conference hosted by the Luye Pharma Group recently took place in Nanjing. Dozens of psychiatrists and experts from 8 countries and regions including China, Korea, Malaysia, and Thaila

BERKELEY, Calif., Sept. 3, 2019 /PRNewswire/ -- The U.S. Patent and Trademark Office (USPTO) today awarded a new CRISPR-Cas9 patent to the University of California (UC), University of Vienna, and Dr. Emmanuelle Charpentier covering compositions of single molecule DNA-targetin